X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Swixx will be responsible for commercializing ORLADEYO in 15 markets within CEE. Orladeyo (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of HAE in adult and pediatric patients 12 years and older.
Lead Product(s): Berotralstat
Therapeutic Area: Genetic Disease Product Name: Orladeyo
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: BioCryst Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 23, 2023
Details:
Swixx BioPharma will exclusively distribute DANYELZA to treat patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in Eastern Europe, including Russia.
Lead Product(s): Naxitamab,Granulocyte-macrophage colony-stimulating factor
Therapeutic Area: Oncology Product Name: DANYELZA
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Y-mAbs Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 18, 2020
Details:
Under the agreement, Swixx will distribute Lojuxta® from October 2020 in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia and Slovakia.
Lead Product(s): Lomitapide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lojuxta
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Amryt Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
